Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2020.09.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical and Pathological Features of Blastic Plasmacytoid Dendritic Cell Neoplasm].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
Objective: To summarize and analyze the clinical features of blastic plasmacytoid dendritic cell neoplasm (BPDCN), so as to enhance the understanding of this disease.
Methods: The clinical manifestations, immunophenotype, pathological features, treatment and prognosis of 11 cases of BPDCN were retrospectively analyzed.
Results: Among the 11 patients diagnosed with BPDCN, there were 8 males and 3 females, with a median age of 44 (6-81) years.
The Challenge of Diagnosing Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.
Anticancer Res
January 2025
Department of Hematology/Oncology, Luminis Health Anne Arundel Medical Center, Annapolis, MD, U.S.A.
Background/aim: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic cancer which is difficult to diagnose and has a lot of overlapping features with other diseases, particularly acute myeloid leukemia (AML). BPDCN shares several immunophenotypic markers with AML, such as CD4, CD56, CD123, and HLA-DR, stating the importance of having extending panel of specific immunohistochemical (IHC) markers.
Case Report: This report details a case of CLL who presented with worsening symptoms of recurrent infections and leukocytosis.
Acute Myeloid Leukemia (AML) With T-Cell Differentiation Arising From Chronic Myelomonocytic Leukemia (CMML).
Case Rep Hematol
December 2024
Department of Pathology and Laboratory Medicine, University of California Irvine (UCI) Medical Center, Orange, USA.
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm characterized by peripheral blood monocytosis and bone marrow dysplasia. In approximately one-fourth of cases, CMML can demonstrate progression to acute myeloid leukemia (AML), referred to as AML ex CMML. We present a 58-year-old woman with a past medical history of idiopathic thrombocytopenic purpura (ITP) who demonstrated 24% bone marrow blasts on a repeat biopsy obtained two years after being diagnosed with CMML.
View Article and Find Full Text PDFHoning CAR T cells to tackle acute myeloid leukemia.
Blood
December 2024
MSKCC, New York, New York, United States.
Acute myeloid leukemia (AML) remains a dismal disease with poor prognosis, particularly in the relapsed/refractory (r/r) setting. Chimeric antigen receptor (CAR) therapy has yielded remarkable clinical results in other leukemias and thus has, in principle, the potential to achieve similar outcomes in r/r AML. Re-directing the approved CD19-specific CAR designs against the myeloid antigens CD33, CD123 or CLEC12A has occasionally yielded morphological leukemia-free states (MLFS) but has so far been marred by threatening myeloablation and early relapses.
View Article and Find Full Text PDFCD33-CD123 IF-THEN gating reduces toxicity while enhancing the specificity and memory phenotype of AML-targeting CAR-T cells.
Blood Cancer Discov
December 2024
Children's Hospital of Los Angeles, Los Angeles, CA, United States.
CAR T-cell therapy has remarkably succeeded in treating lymphoblastic leukemia. However, its success in AML remains elusive due to the risk of on-target off-tumor toxicity to hematopoietic stem and progenitor cells (HSPC) and insufficient T-cell persistence and longevity. Using a SynNotch circuit, we generated a high-precision "IF-THEN" gated logical circuit against the combination of CD33 and CD123 AML antigens and demonstrated anti-tumor efficacy against AML cell lines and patient-derived xenografts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!